

Headquarters



全国免费电话: 400-668-6834
电话: 021-68591985
订购及询单: info@selleck.cn



Toll Free: +1 877 796-6397
Fax: +1 832 582-8590
E-mail: sales@selleckchem.com



小分子化合物库



使用Selleck产品发表的顶级学术期刊 (Science, Nature和 Cell) 文献已达206篇 !

Nature, 2019, 572(7768):254-259
Nature, 2019, 10.1038/s41586-019-1472-0
Nature, 2019, 572(7769):335-340
Nature, 2019, 572(7770):538-542
Nature, 2019, 569(7757):509-513
Nature, 2019, 569(7756):423-427
Nature, 2019, 567(7748):405-408
Nature, 2019, 566(7743):270-274
Nature, 2019, 566(7744):344-349
Nature, 2019, 567(7749):521-524
Nature, 2019, 567(7749):540-544
Nature, 2019, 567(7747):262-266
Nature, 2019, 567(7746):118-122
Nature, 2019, 565(7741):659-663
Nature, 2019, 565(7740):505-510
Nature, 2018, 563(7730):265-269
Nature, 2018, 563(7733):701-704
Nature, 2018, 563(7729):131-136
Nature, 2018, 559(7713):211-216
Nature, 2018, 560(7716):112-116
Nature, 2018, 559(7713):285-289
Nature, 2018, 560(7718):387-391
Nature, 2018, 561(7724):551-555
Nature, 2018, 560(7718):325-330
Nature, 2018, 560(7716):117-121
Nature, 2018, 560(7719):499-503
Nature, 2018, 558(7708):141-145
Nature, 2018, 559(7713):279-284
Nature, 2018, 555(7694):103-106
Nature, 2018, 554(7692):317-322
Nature, 2018, 555(7698):673-677
Nature, 2018, 555(7696):387-391
Nature, 2018, 556(7702):501-504
Nature, 2018, 557(7704):247-251
Nature, 2018, 557(7704):256-260
Nature, 2018, 553(7686):101-105
Nature, 2018, 553(7686):96-100
Nature, 2018, 553(7686):91-95
Nature, 2017, 545(7652):54-59
Nature, 2017, 547(7664):453-457
Nature, 2017, 549(7673):548-552
Nature, 2017, 549(7673):533-537
Nature, 2017, 551(7679):247-250
Nature, 2017, 550(7675):270-274
Nature, 2017, 552(7683):121-125
Nature, 2017, 550(7677):534-538
Nature, 2017, 552(7683):116-120
Nature, 2017, 551(7678):105-109
Nature, 2017, 551(7682):639-643
Nature, 2017, 550(7674):133-136
Nature, 2017, 550(7676):360-365
Nature, 2017, 548(7668):466-470
Nature, 2017, 549(7672):404-408
Nature, 2017, 548(7669):582-587
Nature, 2017, 548(7668):471-475
Nature, 2017, 548(7667):343-346
Nature, 2017, 546(7658):431-435
Nature, 2017, 546(7658):416-420
Nature, 2017, 545(7654):365-369
Nature, 2017, 543(7647):728-732
Nature, 2017, 541(7638):481-487
Nature, 2017, 542(7641):362-366
Nature, 2017, 545(7654):360-364
Nature, 2017, 546(7658):370-375
Nature, 2017, 547(7661):109-113
Nature, 2017, 548(7665):112-116
Nature, 2017, 544(7651):493-497
Nature, 2016, 539(7627):54-58
Nature, 2016, 540(7631):119-123
Nature, 2016, 539(7629):437-442
Nature, 2016, 539(7628):304-308
Nature, 2016, 538(7626):477-482
Nature, 2016, 535(7613):517-22
Nature, 2016, 537(7620):422-426
Nature, 2016, 530(7590):358-61
Nature, 2016, 534(7607):341-6
Nature, 2016, 32(7597):107-11
Nature, 2016, 531(7596):651-5
Nature, 2016, 534(7607):407-411
Nature, 2016, 529(7587):532-6
Nature, 2016, 529(7586):413-417
Nature, 2016, 540(7632):270-275
Nature, 2016, 536(7616):338-43
Nature, 2015, 528(7582):422-6
Nature, 2015, 522(7557):492-6
Nature, 2015, 527(7576):100-4
Nature, 2015, 522(7556):349-53
Nature, 2015, 521(7552):316-21
Nature, 2015, 521(7553):541-4
Nature, 2015, 520(7549):683-7
Nature, 2015, 518(7538):254-7
Nature, 2015, 517(7534):391-5
Nature, 2015, 522(7555):226-30
Nature, 2015, 523(7558):92-5
Nature, 2015, 521(7552):357-61
Nature, 2015, 520(7547):368-72
Nature, 2015, 524(7566):471-5
Nature, 2015, 517(7536):583-8
Nature, 2015, 519(7543):370-3
Nature, 2015, 525(7567):56-61
Nature, 2015, 521(7550):43-7
Nature, 2015, 521(7551):232-6
Nature, 2015, 519(7541):57-62
Nature, 2015, 523(7559):183-188
Nature, 2015, 517(7535):460-5
Nature, 2014, 516(7530):254-8
Nature, 2013, 502(7471):327-332
Nature, 2013, 504(7478):138-42
Nature, 2011, 470(7334):419-23
Nature, 2010, 468(7326):973-7
Science, 2019, 365(6454)
Science, 2019, 364(6441)
Science, 2019, 363(6434)
Science, 2019, 363(6429)
Science, 2018, 362(6417)
Science, 2018, 361(6405)
Science, 2018, 359(6378)
Science, 2017, 358(6367):eaan4368
Science, 2017, eaal3755
Science, 2017, 355(6320):78-83
Science, 2017, 355(6320):84-88
Science, 2016, 354(6315)
Science, 2016, 351(6277):aad3680
Science, 2016, 352(6283):353-8
Science, 2016, 352(6282):189-96
Science, 2016, 353(6302):929-32
Science, 2016, 352(6288):aad3018
Science, 2014, 344(6183):1252304
Cell, 2019, 178(5):1102-1114
Cell, 2019, 178(3):585-599.e15
Cell, 2019, 178(4):807-819.e21
Cell, 2019, 178(2):302-315.e23
Cell, 2019, 176(6):1379-1392
Cell, 2019, 176(3):505-519
Cell, 2019, 176(5):1158-1173
Cell, 2019, 176(5):1098-1112
Cell, 2019, 176(4):869-881
Cell, 2019, 176(5):1143-1157
Cell, 2019, 176(6):1447-1460
Cell, 2019, 176(5):1083-1097
Cell, 2018, 10.1016/j.cell.2018.11.011
Cell, 2018, 175(5):1336-1351
Cell, 2018, 175(5):1244-1258
Cell, 2018, 174(6):1477-1491
Cell, 2018, 174(5):1200-1215
Cell, 2018, 174(5):1127-1142
Cell, 2018, 175(1):186-199
Cell, 2018, 174(2):338-349
Cell, 2018, 174(2):406-421
Cell, 2018, 174(2):422-432
Cell, 2018, 174(2):391-405
Cell, 2018, 175(1):85-100
Cell, 2018, 175(2):429-441
Cell, 2018, 174(4):953-967
Cell, 2018, 174(5):1216-1228
Cell, 2018, 174(4):856-869
Cell, 2018, 175(2):442-457
Cell, 2018, 173(1):104-116
Cell, 2018, 173(1):117-129
Cell, 2018, 173(4):972-988
Cell, 2018, 173(6):1413-1425
Cell, 2018, 173(2):470-484
Cell, 2018, 172(4):857-868
Cell, 2018, 173(2):515-528
Cell, 2018, 172(4):841-856
Cell, 2018, 172(3):564-577
Cell, 2018, 172(3):439-453
Cell, 2018, 172(1-2):90-105
Cell, 2018, 172(3):423-438
Cell, 2017, 171(7):1545-1558
Cell, 2017, 171(7):1611-1624
Cell, 2017, 171(5):1094-1109
Cell, 2017, 171(4):824-835.e18
Cell, 2017, 171(3):628-641
Cell, 2017, 161(4):803-16
Cell, 2017, 171(1):217-228
Cell, 2017, 171(3):668-682
Cell, 2017, 170(5):860-874.e19
Cell, 2017, 170(5):845-859.e19
Cell, 2017, 170(3):507-521.e18
Cell, 2017, 169(2):243-257.e25
Cell, 2017, 169(2):216-228.e19
Cell, 2017, 168(5):856-866
Cell, 2017, 168(1-2):86-100
Cell, 2017, 168(5):890-903
Cell, 2017, 168(3):473-486
Cell, 2017, 170(3):548-563
Cell, 2017, 170(3):564-576
Cell, 2017, 169(6):1105-1118
Cell, 2017, 170(1):185-198
Cell, 2017, 169(1):132-147
Cell, 2017, 168(6):1053-1064
Cell, 2016, 167(1):233-247
Cell, 2016, 167(7):1803-1813
Cell, 2016, 164(1-2):293-309
Cell, 2016, 165(1):234-46
Cell, 2016, 167(7):1734-1749
Cell, 2016, 167(5):1264-1280
Cell, 2015, 162(2):441-51
Cell, 2015, 160(1-2):161-76
Cell, 2015, 161(7):1592-605
Cell, 2015, 162(6):1271-85
Cell, 2014, 157(3):565-79
Cell, 2014, 158(3):564-78



Q1 为何购买Selleck分子库？

使用Selleck分子库发表文章的平均时间约为**两年**，影响因子3~39不等，机制研究的深度要求比同等影响因子的其它文章低。这是一种**短平快**的发文章方法。

学术机构	课题组	历经时间	发表期刊	影响因子
Tsinghua University	YN Du	2y	Nature Materials	39.74
UCSF	JR Chan	1y8m	Nature Medicine	29.89
Roche Innovation Center Basel	CA Cowan	2y4m	Nature Cell Biology	20.06
BC Cancer Agency	S Dedhar	3y	Nature Communications	12.12
Baylor College of Medicine	XH Zhang	1y10m	Nature Communications	12.12
Lund University	JU Kazi	2y8m	Cancer Letters	6.34
University of Wisconsin	X Zhao	1y6m	Stem Cells	5.6
Wuhan Institute of Virology	GF Xiao	1y11m	Journal of Virology	4.66
University of Bergen	BT Gjertsen	1y7m	Pharmacological Research	4.48
University of Nevada	BS Ferguson	1y	Molecular Nutrition & Food Research	4.48
Moffitt Cancer Center	E Schönbrunn	3y	ChemMedChem	3.23
...				
Average		2 years		12.97

Q2 不会使用？

Selleck提供免费的技术咨询/实验设计



Q3 没时间做？

Selleck合作平台为您提供筛选服务：




分子库在疾病研究中的文章案例 I

Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma

作者于2015年5月购买Selleck Kinase Inhibitor Library。本文 (PMID:28764929) 于2017年11月在Gastroenterology (IF:19.23) 发表。


文章背景：诱导细胞坏死是治疗胰腺癌的新思路

胰腺癌细胞本身的抗凋亡机制使得其难以被杀死，因此，一种不依赖于凋亡形式的细胞死亡方式——细胞坏死，引起了广泛关注。开发诱导肿瘤细胞坏死的药物，成了治疗胰腺癌的新思路。



实验设计

一. 高通量药物筛选




化合物库：Selleck Kinase Inhibitor Library

模型：人类胰腺导管腺癌细胞PANC1


指标：细胞活力和细胞死亡实验确定CCT137690能杀死人类胰腺导管腺癌细胞

三. 机制研究




AURKA能结合RIPK1/RIPK3坏死复合体，抑制坏死。AURKA被CCT137690抑制后，肿瘤细胞坏死被激活。

二. 表型研究



1. 细胞形态研究
2. 克隆形成实验

四. 体内效果验证




分子库在疾病研究中的文章案例 II

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection

作者于2015年9月购买Selleck FDA-approved Drug Library，并于4年内发表3篇文章。本文 (PMID: 28814523) 于2017年8月在Journal of Virology (IF:4.324) 发表。


文章背景：某种疾病缺乏有效治疗手段

乙型脑炎由乙脑病毒 (Japanese encephalitis virus, JEV) 引起，除疫苗接种预防外，对于已发病的患者，仍然没有针对性的特效药或治疗手段。



实验设计

一. 高通量药物筛选




化合物库：Selleck FDA-approved Drug Library

模型：带有荧光素酶报告基因的JEV感染性克隆


指标：抑制率>90%，存活率>80%，效果与剂量相关等筛选到5种药物，其中3种为钙离子通道抑制剂

三. 机制研究




1. 用其他钙离子通道抑制剂能起到类似作用
2. 确定药物对JEV的靶点

二. 表型研究



1. 剂量-效果关系验证
2. 时间-效果关系验证
3. 抗病毒作用谱研究

四. 体内效果验证




FDA药物库 FDA-approved Drug Library Cat.No. L1300

- 2576个FDA批准的原料药的独特集合
- 生物安全性和有效性得到临床试验的验证

规格 (预溶于DMSO或水)
100 μ L/well (2 mM 或 10 mM 溶液)

定制您的分子库

- 特定化合物
- 数量
- 96孔板位图
- 规格：干粉或DMSO溶液



使用该分子库发表的文章

Mov Disord,2019,34(3):323-334
Cancer Lett,2019,451:79-91
Cell Chem Biol,2019,26(5):699-710
Mol Cancer Ther,2019,10.1158/1535-7163
Antiviral Res,2019,161:1-9
Biochem Pharmacol,2019,168:224-236
Acta Pharmacol Sin,2019,10.1038/s41401-019-0231-y
RSC Adv,2019,1696-1704
Med Mycol,2019,10.1093/mmy/myz077
Biochem Biophys Res Commun,2019,515(1):92-98
Virus Res,2019,263:102-111
Assay Drug Dev Technol,2019,17(1):14-16
Cancer Res,2018,78(15):4370-4385
Br J Pharmacol,2018,175(2):168-180
EBioMedicine,2018,36:241-251
EBioMedicine,2018,37:344-355
ACS Infect Dis,2018,4(4):635-645
J Lipid Res,2018,59(10):1916-1926
Antiviral Res,2018,157:57-67
Antimicrob Agents Chemother,2018,62(1)
J Cell Physiol,2018,233(5):3713-3722
J Cell Physiol,2018,233(1):422-433
Mol Cell Endocrinol,2018,460:229-237
PLoS One,2018,13(11):e0207872
Eur J Clin Microbiol Infect Dis,2018,37(1):141-148
Protein Expr Purif,2018,150:12-16
Nat Med,2017,23(4):405-408
Drug Discov Today,2017,22(2):199-203
Cell Death Dis,2017,8(6):e2904
J Virol,2017,e01055-17
Antiviral Res,2017,146:76-85
Sci Rep,2017,7(1):525
Clin Cancer Res,2016,10.1158/1078-0432
PLoS Negl Trop Dis,2016,10(4):e0004584
Antiviral Res,2016,135:81-90
Antimicrob Agents Chemother,2016,60(11):6532-6539
Antimicrob Agents Chemother,2015,60(2):862-72
Int J Mass Spectrom,2015,377:719-717
Clin Exp Metastasis,2016,33(4):385-99
Pancreas,2015,44(1):152-7
PLoS One,2015,10(6):e0129234
Nat Prod Rep,2014,31(6):718-29
Cancer Res,2014,74:1702
Cell Death Discov,2016,2:16041
PLoS One,2015,10(11):e0143033
Antimicrob Agents Chemother,2014,58(8):4875-84
PLoS One,2014,9(6):e99440
PLoS One,2016,11(2):e0149848
Nat Med,2014,20(8):954-60
Biochem Biophys Res Commun,2014,452(3):315-21
Sensors (Basel),2016,16(3)
Clin Cancer Res,2015,21(5):1172-82
PLoS One,2015,10(11):e0142655
Oncotarget,2015,6(3):1531-43
Pharmacol Res,2016,113(Pt A):216-227
Mol Cancer Ther,2015,14(5):1213-23
Oncotarget,2014,5(15):6512-25
Biosens Bioelectron,2015,68:699-704
Curr Protoc Chem Biol,2014,4:177-191
Anal Chem,2017,89(12):6678-6685
Cell Cycle,2015,14(1):109-22
Sci Rep,2018,8(1):13106
Mol Cancer Res,2014,12(5):703-13
Cancer Sci,2018,109(4):1220-1229
Antimicrob Agents Chemother,2017,62(1)
Head Neck,2015,37(12):1722-32
Cell Rep,2018,22(5):1185-1199
Kaohsiung J Med Sci,2019,10.1002/kjm2.12051
Neurobiol Aging,2019,76:24-34
Neuropharmacology,2019,10.1038/s41386-018-0266-7
Breast Cancer Res,2019,21(1):37
Sci Adv,2019,5(6):eaav9784
Bioengineered,2019,10(1):98-107


临床前和临床药物库 Preclinical and Clinical Compound Library Cat.No. L3900

- 2578个临床化合物的独特集合
- 包括正在进行临床前研究的药物分子、临床期的药物分子和已经上市的药物

规格 (预溶于DMSO或水)
100 μ L/well (2 mM 或 10 mM 溶液)

定制您的分子库

- 特定化合物
- 数量
- 96孔板位图
- 规格：干粉或DMSO溶液



使用该分子库发表的文章

Sci Adv,2019,5(6):eaav9784
Neuropsychopharmacology,2019,10.1038/s41386-018-0266-7
Breast Cancer Res,2019,21(1):37
Neurobiol Aging,2019,76:24-34
Bioengineered,2019,10(1):98-107
Kaohsiung J Med Sci,2019,10.1002/kjm2.12051
Cell Rep,2018,22(5):1185-1199
Cancer Sci,2018,109(4):1220-1229
Sci Rep,2018,8(1):13106
J Cell Physiol,2018,233(1):422-433
Anal Chem,2017,89(12):6678-6685
Antimicrob Agents Chemother,2017,62(1)
Pharmacol Res,2016,113(Pt A):216-227
PLoS One,2016,11(2):e0149848
Sensors (Basel),2016,16(3)
Clin Cancer Res,2015,21(5):1172-82
Biosens Bioelectron,2015,68:699-704
Mol Cancer Ther,2015,14(5):1213-23
Cell Cycle,2015,14(1):109-22
PLoS One,2015,10(11):e0142655
Oncotarget,2015,6(3):1531-43
Head Neck,2015,37(12):1722-32
Nat Med,2014,20(8):954-60
Mol Cancer Res,2014,12(5):703-13
Oncotarget,2014,5(15):6512-25
Curr Protoc Chem Biol,2014,4:177-191

代谢化合物库 Metabolism Compound Library Cat.No. L3700

- 1383个代谢相关的活性化合物的独特集合，包括抑制剂和人类内源代谢物
- 涵盖糖代谢、脂质代谢、蛋白质水解、核苷酸代谢等多个代谢途径
- 涉及200多个靶点，如FXR、DPP-4、葡萄糖激酶、HSP、PDE、PPAR等

规格 (预溶于DMSO或水)		定制您的分子库			
100 μ L/well	(2 mM 或 10 mM 溶液)				
		特定化合物	数量	96孔板位图	规格： 干粉或DMSO溶液




使用该分子库发表的文章

Sci Adv ,2019,5(6):eaav9784	PLoS One ,2016,11(2):e0149848
Neuropsychopharmacology ,2019,10.1038/s41386-018-0266-7	Sensors (Basel) ,2016,16(3)
Breast Cancer Res ,2019,21(1):37	Clin Cancer Res ,2015,21(5):1172-82
Neurobiol Aging ,2019,76:24-34	Biosens Bioelectron ,2015,68:699-704
Bioengineered ,2019,10(1):98-107	Mol Cancer Ther ,2015,14(5):1213-23
Kaohsiung J Med Sci ,2019,10.1002/kjm2.12051	Cell Cycle ,2015,14(1):109-22
Cell Rep ,2018,22(5):1185-1199	PLoS One ,2015,10(11):e0142655
Cancer Sci ,2018,109(4):1220-1229	Oncotarget ,2015,6(3):1531-43
Sci Rep ,2018,8(1):13106	Head Neck ,2015,37(12):1722-32
J Cell Physiol ,2018,233(1):422-433	Nat Med ,2014,20(8):954-60
Nat Med ,2017,23(4):405-408	Mol Cancer Res ,2014,12(5):703-13
Anal Chem ,2017,89(12):6678-6685	Oncotarget ,2014,5(15):6512-25
Antimicrob Agents Chemother ,2017,e01674-17	Curr Protoc Chem Biol ,2014,4:177-191
Pharmacol Res ,2016,113(Pt A):216-227	

激酶药物库 Kinase Inhibitor Library Cat.No. L1200

- 1188个激酶相关的活性化合物的独特集合
- 包括有生物研究的小分子，临床期的药物分子和已经上市的药物
- 靶点包括EGFR、PI3K、Aurora Kinase、CDK和MEK等

规格 (预溶于DMSO或水)		定制您的分子库			
100 μ L/well	(2 mM 或 10 mM 溶液)				
		特定化合物	数量	96孔板位图	规格： 干粉或DMSO溶液



使用该分子库发表的文章

Nat Commun ,2019,10(1):2197	J Biol Chem ,2017,292(41):17037-17045
Sci Adv ,2019,5(6):eaav9784	Front Plant Sci ,2017,10.3389/fpls.2017.00852.
NPJ Genom Med ,2019,4:7	ChemMedChem ,2017,12(22):1857-1865
Neuropsychopharmacology ,2019,10.1038/s41386-018-0266-7	Biochem Biophys Res Commun ,2017,493(1):58-63
J Exp Clin Cancer Res ,2019,21(1):56	J Mol Cell Cardiol ,2016,97:106-13
Breast Cancer Res ,2019,21(1):37	Pharmacol Res ,2016,113(Pt A):216-227
Development ,2019,146(14)	ChemMedChem ,2016,11(11):1137-44
Neurobiol Aging ,2019,76:24-34	ChemMedChem ,2016,10.1002/cmcd
Anal Biochem ,2019,569:46-52	Bioorg Med Chem ,2016,24(19):4647-51
Bioengineered ,2019,10(1):98-107	PLoS One ,2016,11(2):e0149848
Kaohsiung J Med Sci ,2019,10.1002/kjm2.12051	Sensors (Basel) ,2016,16(3)
Methods Mol Biol ,2019,1888:115-126	Clin Cancer Res ,2015,21(5):1172-82
Methods Mol Biol ,2019,1888:21-43	Biosens Bioelectron ,2015,68:699-704
Cell Rep ,2018,22(5):1185-1199	J Control Release ,2015,204:20-9
Mol Cancer Ther ,2018,10.1158/1535-7163.MCT-18-0179	Oncogene ,2015,34(32):4199-210
Stem Cell Res Ther ,2018,9(1):319	Mol Cancer Ther ,2015,14(5):1213-23
Cancer Sci ,2018,109(4):1220-1229	Breast Cancer Res Treat ,2015,149(3):715-26
Antimicrob Agents Chemother ,2018,10.1128/AAC.01744-18	Cell Cycle ,2015,14(1):109-22
Hum Gene Ther ,2018,29(8):886-901	BMC Cancer ,2015,15:239
Sci Rep ,2018,8(1):13106	PLoS One ,2015,10(11):e0142655
J Cell Physiol ,2018,233(1):422-433	Head Neck ,2015,37(12):1722-32
Cell Stress ,2018,10.15698/cst2018.04.131	Oncotarget ,2015,6(3):1531-43
FEBS Open Bio ,2018,9(1):82-91	Nat Med ,2014,20(8):954-60
Antiviral Res ,2018,158:226-237	Mol Cancer Ther ,2014,13(2):353-63
Nat Med ,2017,23(4):405-408	Mol Cancer Res ,2014,12(5):703-13
Gastroenterology ,2017,153(5):1429-1443	ACS Chem Biol ,2014,9(5):1160-71
Nat Commun ,2017,8:15289	PLoS One ,2014,9(7):e102741
Cell Rep ,2017,21(9):2639-2646	Mol Med Rep ,2014,10(6):3348-56
Cancer Lett ,2017,405:73-78	Oncotarget ,2014,5(15):6512-25
Anal Chem ,2017,89(12):6678-6685	Curr Protoc Chem Biol ,2014,4:177-191
J Mol Biol ,2017,429(13):2042-2045	PLoS One ,2013,8(5):e63240
Biochim Biophys Acta ,2017,1861(4):947-957	PLoS One ,2013,8(4):e60334
Antimicrob Agents Chemother ,2017,62(1)	

天然产物库 Natural Product Library Cat.No. L1400

- 2116个天然产物的独特集合
- 毒副作用小，易吸收
- 经报道具有药理活性和药用价值

规格 (预溶于DMSO或水)

100 μ L/well (2 mM 或 10 mM 溶液)



定制您的分子库



特定化合物




数量



96孔板位图



规格：
干粉或DMSO溶液



使用该分子库发表的文章

- | | |
|---|--|
| Sci Adv ,2019,5(6):eaav9784 | Nat Med ,2017,23(4):405-408 |
| Cell Rep ,2019,26(6):1544-1556 | Anal Chem ,2017,89(12):6678-6685 |
| Neuropsychopharmacology ,2019,10.1038/s41386-018-0266-7 | Mol Nutr Food Res ,2017,61(4) |
| Cancer Lett ,2019,459:50-58 | Antimicrob Agents Chemother ,2017,e01674-17 |
| Protein Cell ,2019,10(6):417-435 | PeerJ ,2017,5:e3283 |
| Breast Cancer Res ,2019,21(1):37 | Pharmacol Res ,2016,113(Pt A):216-227 |
| Oncogenesis ,2019,8(3):14 | PLoS One ,2016,11(2):e0149848 |
| Neurobiol Aging ,2019,76:24-34 | Biochem Biophys Res Commun ,2016,473(4):775-80 |
| Sci China Life Sci ,2019,10.1007/s11427-018-9477-3 | Sensors (Basel) ,2016,16(3) |
| Bioengineered ,2019,10(1):98-107 | Cytotechnology ,2016,68(4):1633-40 |
| Kaohsiung J Med Sci ,2019,10.1002/kjm2.12051 | Clin Cancer Res ,2015,21(5):1172-82 |
| bioRxiv ,2019,10.1101/517086 | Biosens Bioelectron ,2015,68:699-704 |
| Cell Rep ,2018,22(5):1185-1199 | Mol Cancer Ther ,2015,14(5):1213-23 |
| Mol Neurobiol ,2018,10.1007/s12035-018-0953-8 | PLoS Negl Trop Dis ,2015,9(6):e0003878 |
| Cancer Sci ,2018,109(4):1220-1229 | Cell Cycle ,2015,14(1):109-22 |
| Antiviral Res ,2018,S0166-3542(18)30404-2 | PLoS One ,2015,10(11):e0142655 |
| Sci Rep ,2018,8(1):13106 | Oncotarget ,2015,6(3):1531-43 |
| Int J Biol Sci ,2018,10.7150/ijbs | Head Neck ,2015,37(12):1722-32 |
| Int J Biol Sci ,2018,14(11):1521-1534 | Nat Med ,2014,20(8):954-60 |
| J Biol Chem ,2018,10.1074/jbc.RA118.006986 | Mol Cancer Res ,2014,12(5):703-13 |
| J Cell Physiol ,2018,233(1):422-433 | Oncotarget ,2014,5(15):6512-25 |
| Int J Biol Macromol ,2018,116:173-181 | Curr Protoc Chem Biol ,2014,4:177-191 |
| Sci Rep ,2018,8(1):14178 | |

免疫/炎症分子化合物库 Immunology/Inflammation Compound Library Cat.No. L4100

- 1091个与免疫炎症相关的活性化合物的独特集合
- 包括有生物研究的分子、临床期的药物分子和已经上市的药物
- 靶点包含COX、Nrf2、CXCR、ROS、TLR、p38 MAPK、NOS等

规格 (预溶于DMSO或水)

100 μ L/well (2 mM 或 10 mM 溶液)



定制您的分子库



特定化合物




数量



96孔板位图



规格：
干粉或DMSO溶液



使用该分子库发表的文章

- | | |
|---|---|
| Sci Adv ,2019,5(6):eaav9784 | PLoS One ,2016,11(2):e0149848 |
| Neuropsychopharmacology ,2019,10.1038/s41386-018-0266-7 | Sensors (Basel) ,2016,16(3) |
| Breast Cancer Res ,2019,21(1):37 | Clin Cancer Res ,2015,21(5):1172-82 |
| Neurobiol Aging ,2019,76:24-34 | Biosens Bioelectron ,2015,68:699-704 |
| Bioengineered ,2019,10(1):98-107 | Mol Cancer Ther ,2015,14(5):1213-23 |
| Kaohsiung J Med Sci ,2019,10.1002/kjm2.12051 | Cell Cycle ,2015,14(1):109-22 |
| Cell Rep ,2018,22(5):1185-1199 | PLoS One ,2015,10(11):e0142655 |
| Cancer Sci ,2018,109(4):1220-1229 | Oncotarget ,2015,6(3):1531-43 |
| Sci Rep ,2018,8(1):13106 | Head Neck ,2015,37(12):1722-32 |
| J Cell Physiol ,2018,233(1):422-433 | Nat Med ,2014,20(8):954-60 |
| Anal Chem ,2017,89(12):6678-6685 | Mol Cancer Res ,2014,12(5):703-13 |
| Antimicrob Agents Chemother ,2017,62(1) | Oncotarget ,2014,5(15):6512-25 |
| Pharmacol Res ,2016,113(Pt A):216-227 | Curr Protoc Chem Biol ,2014,4:177-191 |

已知活性药物库- I Bioactive Compound Library- I Cat.No. L1700

- 6734个具有生物活性的化合物的独特集合
- 包括有生物研究的分子，临床期的药物分子和已经上市的药物
- 活性明确，信息全面，是基础机制研究的有力工具

规格 (预溶于DMSO或水)

100 μ L/well (2 mM 或 10 mM 溶液)



定制您的分子库



特定化合物



数量



96孔板位图



规格：
干粉或DMSO溶液



使用该分子库发表的文章

[Sci Adv](#),2019,5(6):eaav9784

[Neuropsychopharmacology](#),2019,10.1038/s41386-018-0266-7

[Breast Cancer Res](#),2019,21(1):37

[Neurobiol Aging](#),2019,76:24-34

[RSC Adv](#),2019,1696-1704

[Vet Parasitol](#),2019,265:15-18

[Bioengineered](#),2019,10(1):98-107

[Kaohsiung J Med Sci](#),2019,10.1002/kjm2.12051

[Cell Rep](#),2018,22(5):1185-1199

[Cell Chem Biol](#),2018,25(2):175-184

[Cancer Sci](#),2018,109(4):1220-1229

[Sci Rep](#),2018,8(1):13106

[J Cell Physiol](#),2018,233(1):422-433

[Invest New Drugs](#),2018,36(4):590-600

[Mol Immunol](#),2018,101:86-91

[Trends Microbiol](#),2018,10.1016/j.tim.2018.04.004

[Nat Med](#),2017,23(4):405-408

[Anal Chem](#),2017,89(12):6678-6685

[Dis Model Mech](#),2017,10(9):1155-1164

[Antimicrob Agents Chemother](#),2017,62(1)

[Transl Oncol](#),2017,10(4):546-554

[Pharmacol Res](#),2016,113(Pt A):216-227

[PLoS One](#),2016,11(2):e0149848

[Sensors \(Basel\)](#),2016,16(3)

[Sci Rep](#),2016,6:33427

[Clin Cancer Res](#),2015,21(5):1172-82

[Biosens Bioelectron](#),2015,68:699-704

[Mol Cancer Ther](#),2015,14(5):1213-23

[Cell Cycle](#),2015,14(1):109-22

[PLoS One](#),2015,10(11):e0142655

[J Biomol Screen](#),2015,20(9):1171-7

[Oncotarget](#),2015,6(3):1531-43

[Head Neck](#),2015,37(12):1722-32

[Nat Med](#),2014,20(8):954-60

[Mol Cancer Res](#),2014,12(5):703-13

[Oncotarget](#),2014,5(15):6512-25


[Curr Protoc Chem Biol](#),2014,4:177-191

生物活性库- II Bioactive Compound Library- II (Provided by Pfizer) Cat.NO. L1700-II

- 5309个具有生物活性的化合物的独特集合
- 化合物来源于辉瑞
- 靶点丰富且有别于L1700，结构多样，透膜性好

规格 (预溶于DMSO)

30 μ L/well (10 mM 溶液)



使用该分子库发表的文章

[Sci Adv](#),2019,5(6):eaav9784

[Neuropsychopharmacology](#),2019,10.1038/s41386-018-0266-7

[Breast Cancer Res](#),2019,21(1):37

[Neurobiol Aging](#),2019,76:24-34

[Bioengineered](#),2019,10(1):98-107

[Kaohsiung J Med Sci](#),2019,10.1002/kjm2.12051

[Cell Rep](#),2018,22(5):1185-1199

[Cancer Sci](#),2018,109(4):1220-1229

[Sci Rep](#),2018,8(1):13106

[J Cell Physiol](#),2018,233(1):422-433

[Anal Chem](#),2017,89(12):6678-6685

[Antimicrob Agents Chemother](#),2017,62(1)

[Pharmacol Res](#),2016,113(Pt A):216-227

[PLoS One](#),2016,11(2):e0149848

[Sensors \(Basel\)](#),2016,16(3)

[Clin Cancer Res](#),2015,21(5):1172-82

[Biosens Bioelectron](#),2015,68:699-704

[Mol Cancer Ther](#),2015,14(5):1213-23

[Cell Cycle](#),2015,14(1):109-22

[PLoS One](#),2015,10(11):e0142655

[Oncotarget](#),2015,6(3):1531-43

[Head Neck](#),2015,37(12):1722-32

[Nat Med](#),2014,20(8):954-60

[Mol Cancer Res](#),2014,12(5):703-13

[Oncotarget](#),2014,5(15):6512-25

[Curr Protoc Chem Biol](#),2014,4:177-191










多样性化合物母核库 Express-Pick Library (Provided by Pfizer) [Cat.No. L3600](#)

- 4208个不同母核结构的创新型化合物
- 化合物来源于辉瑞
- 多样的结构及药效基团增大了与生物靶点的有效结合

规格 (预溶于DMSO)

100 μ L/well (10 mM 溶液)

Express-Pick Library 组成

结构	名称	ID	化学式	分子量
	WAY-216050	1	$C_{23}H_{22}ClFN_2O_4$	444.8831832
	WAY-312414	2	$C_{14}H_{16}N_2O_2S$	276.35404
	WAY-217028	3	$C_{19}H_{16}ClF_3N_2O_4$	428.7895496
	WAY-312092	4	$C_{15}H_{18}N_2OS$	274.38122
	WAY-312398	5	$C_{20}H_{15}NO_4$	333.3374
	WAY-311274	6	$C_{17}H_{15}ClN_2O_2S$	346.8312
	GI-523285	7	$C_{14}H_{12}N_2OS$	256.32288
	WAY-312818	8	$C_{15}H_{10}Cl_3NO_3S$	390.6688
	WAY-312684	9	$C_{16}H_{13}Cl_2NO_3S$	370.25032
...				

其它化合物库

HTS Library for Drug Discovery (Provided by Pfizer) [Cat.NO. L5000](#)

包含了99040个结构多样的创新型化合物的独特集合

Human Endogenous Metabolite Compound Library [Cat.No. L4500](#)

408个人类内源代谢物的小分子的独特集合

Drug Repurposing Library [Cat.No. L3800](#)

2833个已经上市或通过临床期的药物集合

Fragment Library [Cat.No. L1600](#)

1015个片段小分子的独特集合

Angiogenesis Related compound Library [Cat.No. L5200](#)

113个与血管生成相关的活性化合物的独特集合

Anti-cancer Compound Library [Cat.No. L3000](#)

1966个处于临床实验阶段的抗肿瘤化合物的独特集合

Cambridge Cancer Compound Library [Cat.No. L2300](#)

247个高附加值的抗癌化合物的独特集合

Anti-cancer Metabolism Compound Library [Cat.No. L5700](#)

198个用于癌症代谢研究的活性化合物的独特集合

Small Molecule Immuno-Oncology Compound Library [Cat.No. L4800](#)

92个肿瘤免疫小分子的独特集合

Cell Cycle compound library [Cat.No. L5100](#)

121个与细胞周期相关的活性化合物的独特集合

DNA Damage/DNA Repair compound Library [Cat.No. L4600](#)

179个用于DNA损伤和修复研究的活性化合物的独特集合

Antibiotics compound Library [Cat.No. L5300](#)

308个抗生素的独特集合

Anti-infection Compound Library [Cat.No. L3100](#)

938个具有抗感染活性的化合物的独特集合

Anti-alzheimer's Disease Compound Library [Cat.No. L5900](#)

490个用于研究阿尔茨海默症的活性化合物的独特集合

Anti-diabetic Compound Library [Cat.No. L2900](#)

155个与糖尿病发展相关的活性化合物的独特集合

Inhibitor Library [Cat.No. L1100](#)

2790个最新抑制剂的独特集合

Highly Selective Inhibitor Library [Cat.No. L3500](#)

320个高选择性的小分子抑制剂的独特集合

Covalent Inhibitor Library [Cat.No. L5800](#)

81个共价抑制剂的独特集合

其它化合物库

Tyrosine Kinase Inhibitor Library Cat.No. L1800

395个与酪氨酸激酶相关的活性化合物的独特集合

Protease Inhibitor Library Cat.No. L2500

229个与蛋白酶相关的活性化合物的独特集合

Epigenetics Compound Library Cat.No. L1900

464个与表观研究相关的活性化合物的独特集合

Histone modification compound library Cat.No. L4900

112个与组蛋白修饰相关的活性化合物的独特集合

Ubiquitination Compound Library Cat.No. L6000

153个与泛素化相关的活性化合物的独特集合

Stem Cell Signaling Compound Library Cat.No. L2100

297个与干细胞信号通路相关的活性化合物的独特集合

Autophagy Compound Library Cat.No. L2600

830个与自噬信号通路相关的活性化合物的独特集合

Apoptosis Compound Library Cat.No. L3300

700个靶向Bcl-2, Caspase, p53, TNF-alpha, Mdm2或survivin等凋亡蛋白的活性化合物的独特集合

Neuronal Signaling Compound Library Cat.No. L4000

1111个与神经信号通路相关的活性化合物的独特集合

CNS-Penetrant Compound Library Cat.No. L4700

307个能透过血脑屏障的活性化合物的独特集合

Ion Channel Ligand Library Cat.No. L2700

232个与离子通道配体相关的活性化合物的独特集合

PI3K/Akt Inhibitor Library Cat.No. L2800

174个与PI3K信号通路相关的活性化合物的独特集合

MAPK Inhibitor Library Cat.No. L3400

95个与MAPK信号通路相关的活性化合物的独特集合

GPCR Compound Library Cat.No. L2200

746个与GPCR相关的活性化合物的独特集合

JAK/STAT compound library Cat.No. L5400

51个与JAK-STAT信号通路相关的活性化合物的独特集合

NF-κB Signaling Compound Library Cat.No. L5500

41个与NF-κB信号通路相关的活性化合物的独特集合

TGF-beta/Smad compound library Cat.No. L5600

61个与TGF-β/Smad信号通路相关的活性化合物的独特集合

分子库全球合作伙伴



FAQ

Q1 筛到药以后是否牵涉到专利问题？

化合物本身不牵涉专利问题，当我们提及“筛到药”一般是指筛选到一个药物的新适应症，研发人员完全可以申请专利，与Selleck及原研药厂无关。事实上，老药新用依然是一个比较热门的领域，例如FDA批准用于治疗NSCLC（非小细胞肺癌）的Gefitinib现在有400+临床试验，涉及肺癌、头颈癌、唾液腺癌、食道癌、乳腺癌、肾癌、卵巢癌、结肠癌等众多疾病。

Q2 使用Selleck分子库一般多久能发文章，发什么样的文章？

据Selleck的不完全统计，研究者从购买到发表文章大约需要1-3年的时间，平均2年，而影响因子从3分到39分都有。

Q3 对Selleck分子库感兴趣，但没时间/精力去做怎么办？

Selleck以讲座、技术支持等方式免费为使用者提供培训。对于时间、精力欠缺的客户，我们可以联系相关机构、公司等，提供技术服务。

Q4 为什么Selleck某些化合物库较其他公司分子数少？

Selleck已将溶解度不达标的、违禁品、盐非盐形式以及不相关产品排除，如果看有效分子数，Selleck某些化合物库是更优选择，并且每三个月更新一次。

※ 访问www.selleck.cn，查询更多分子库价格。